Barclays Reiterates Underweight Rating on Illumina, Inc. (ILMN)

Market Context

Illumina, Inc. operates in the Healthcare sector. The stock currently trades at $175.09 with a market capitalization of $20.8B. The stock has gained 93.5% over the past 52 weeks.

Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Illumina, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Illumina, Inc.

Among the 10 most recent ratings: 5 Buy, 2 Hold, 3 Sell.

Date	Firm	Rating	Price Target
Jun 24, 2026	Barclays	Underweight	N/A
Jun 10, 2026	JP Morgan	Overweight	N/A
Jun 01, 2026	Guggenheim	Buy	N/A
May 15, 2026	RBC Capital	Outperform	N/A
May 04, 2026	Citigroup	Sell	N/A

Related Tools: Analyst Ratings Dashboard | View ILMN Stock Page